CRX-526 | CAS#245515-64-4

MedKoo Cat#: 525370 | Name: CRX-526

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CRX-526 is a TLR4 antagonist, protecting against advanced diabetic nephropathy.

Chemical Structure

CRX-526

CAS#245515-64-4

Theoretical Analysis

MedKoo Cat#: 525370

Name: CRX-526

CAS#: 245515-64-4

Chemical Formula: C69H127N2O19P

Exact Mass: 1318.8771

Molecular Weight: 1319.74

Elemental Analysis: C, 62.80; H, 9.70; N, 2.12; O, 23.03; P, 2.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CRX-526; CRX 526; CRX526;

IUPAC/Chemical Name

(2S)-2-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-3-[(2R,3R,4R,5S,6R)-3-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-4-[(3R)-3-hexanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid

InChi Key

PRIXXGNJDNLMBH-DPGPRPECSA-N

InChi Code

InChI=1S/C69H127N2O19P/c1-7-13-19-22-25-28-31-34-40-43-54(85-61(75)46-37-16-10-4)49-59(73)70-57(68(79)80)53-84-69-65(71-60(74)50-55(86-62(76)47-38-17-11-5)44-41-35-32-29-26-23-20-14-8-2)67(66(58(52-72)88-69)90-91(81,82)83)89-64(78)51-56(87-63(77)48-39-18-12-6)45-42-36-33-30-27-24-21-15-9-3/h54-58,65-67,69,72H,7-53H2,1-6H3,(H,70,73)(H,71,74)(H,79,80)(H2,81,82,83)/t54-,55-,56-,57+,58-,65-,66-,67-,69-/m1/s1

SMILES Code

O=C(O)[C@@H](NC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O)[C@H]1NC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O

Appearance

unknown

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,319.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang H, Gu J, Hou X, Chen J, Yang N, Liu Y, Wang G, Du M, Qiu H, Luo Y, Jiang Z, Feng L. Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway. Biomed Pharmacother. 2017 Jan;85:531-540. doi: 10.1016/j.biopha.2016.11.061. Epub 2016 Nov 27. PubMed PMID: 27903427. 2: Zhou J, Soltow M, Zimmermann K, Pavlovic D, Johnston B, Lehmann C. Experimental TLR4 inhibition improves intestinal microcirculation in endotoxemic rats. Microvasc Res. 2015 Sep;101:33-7. doi: 10.1016/j.mvr.2015.06.004. Epub 2015 Jun 24. PubMed PMID: 26116862. 3: Huang HY, Zhang ZJ, Cao CB, Wang N, Liu FF, Peng JQ, Ren XJ, Qian J. The TLR4/NF-κB signaling pathway mediates the growth of colon cancer. Eur Rev Med Pharmacol Sci. 2014;18(24):3834-43. PubMed PMID: 25555874. 4: Lin M, Yiu WH, Li RX, Wu HJ, Wong DW, Chan LY, Leung JC, Lai KN, Tang SC. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int. 2013 May;83(5):887-900. doi: 10.1038/ki.2013.11. Epub 2013 Feb 20. PubMed PMID: 23423259. 5: Zanotti G, Casiraghi M, Abano JB, Tatreau JR, Sevala M, Berlin H, Smyth S, Funkhouser WK, Burridge K, Randell SH, Egan TM. Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema. Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L52-63. doi: 10.1152/ajplung.90406.2008. Epub 2009 Apr 17. PubMed PMID: 19376887; PubMed Central PMCID: PMC2711808. 6: Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL, Ryter KT, Cluff CW, Evans JT, Johnson DA. The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4. doi: 10.1016/j.bmcl.2008.09.060. Epub 2008 Sep 19. PubMed PMID: 18835160. 7: Fort MM, Mozaffarian A, Stöver AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005 May 15;174(10):6416-23. PubMed PMID: 15879143.